A streamlined CRISPR/Cas9 approach for fast genome editing in Toxoplasma gondii and Besnoitia besnoiti

© 2020 by the author. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

Toxoplasma gondii (T. gondii) and Besnoitia besnoiti (B. besnoiti) are closely related coccidian parasites belonging to the phylum Apicomplexa, which comprises many other important pathogens of humans and livestock. T. gondii is considered a model organism for studying the cell biology of Apicomplexa mainly due to the ease of propagation in diverse host cells and the availability of a wide range of genetic tools. Conversely, B. besnoiti in vitro culture systems currently exist only for the acute phase of infection, and genetic manipulation has proven much more challenging. In recent years, the targeted editing of chromosomal DNA by the programmable CRISPR-associated (Cas)9 enzyme has greatly improved the scope and accuracy of genetic manipulation in T. gondii and related parasites but is still lagging in B. besnoiti. The CRISPR/Cas9 technology enables the introduction of single point and insertion/deletion mutations, precise integration of in-frame epitope tags, and deletions of genes at reduced time and cost compared to previous methods. Current protocols for CRISPR-mediated genome editing in T. gondii rely on either constitutive or transient expression of Cas9 as well as target specific sgRNAs encoded separately or together on transfected plasmid vectors. Constitutively expressed Cas9 carries the risk of toxicity, whilst the transient approach is laborious and error-prone. Here we present a protocol for plasmid vector-independent genome-editing using chemically synthesized and modified sgRNAs. This protocol allows for rapid, efficient, and cost-effective generation of mutant cell lines of T. gondii and B. besnoiti.

Keywords

Chemical modifications

CRISPR/Cas9

efficiency

parasites

ribonucleoprotein

References

[1] C. A. Hunter and L. D. Sibley, “Modulation of innate immunity by Toxoplasma gondii virulence effectors,” Nat. Rev. Microbiol., vol. 10, no. 11, pp. 766–778, 2012, doi: 10.1038/nrmicro2858.
[2] G. Álvarez-García, C. F. Frey, L. M. O. Mora, and G. Schares, “A century of bovine besnoitiosis: an unknown disease re-emerging in Europe,” Trends Parasitol., vol. 29, no. 8, pp. 407–415, 2013, doi: https://doi.org/10.1016/j.pt.2013.06.002.
[3] F. Jiang and J. A. Doudna, “CRISPR-Cas9 Structures and Mechanisms,” Annu Rev Biophys, vol. 46, pp. 505–529, 2017, doi: 10.1146/annurev-biophys-062215-010822.
[4] M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, and E. Charpentier, “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity,” Science (80-. )., vol. 337, no. 6096, pp. 816–821, 2012, doi: 10.1126/science.1225829.
[5] C. Anders, O. Niewoehner, A. Duerst, and M. Jinek, “Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease,” Nature, vol. 513, no. 7519, pp. 569–573, 2014, doi: 10.1038/nature13579.
[6] B. A. Fox, J. G. Ristuccia, J. P. Gigley, and D. J. Bzik, “Efficient gene replacements in Toxoplasma gondii strains deficient for nonhomologous end joining,” Eukaryot. Cell, vol. 8, no. 4, pp. 520–529, Apr. 2009, doi: 10.1128/EC.00357-08.
[7] B. Shen, K. Brown, S. Long, and L. D. Sibley, “Development of CRISPR/Cas9 for Efficient Genome Editing in Toxoplasma gondii,” in Methods Mol Biol, 2016/10/07., vol. 1498, A. Reeves, Ed. New York, NY: Springer New York, 2017, pp. 79–103.
[8] R. G. Donald and D. S. Roos, “Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria.,” Proc. Natl. Acad. Sci. U. S. A., vol. 90, no. 24, pp. 11703–11707, Dec. 1993, doi: 10.1073/pnas.90.24.11703.
[9] A. Hendel et al., “Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells,” Nat. Biotechnol., vol. 33, no. 9, pp. 985–989, 2015, doi: 10.1038/nbt.3290.
[10] S. Kim, D. Kim, S. W. Cho, J. Kim, and J. S. Kim, “Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins,” Genome Res., vol. 24, no. 6, pp. 1012–1019, 2014, doi: 10.1101/gr.171322.113.
[11] D. A. Braasch et al., “RNA Interference in Mammalian Cells by Chemically-Modified RNA †,” Biochemistry, vol. 42, no. 26, pp. 7967–7975, 2003, doi: 10.1021/bi0343774.
[12] R. S. Geary, D. Norris, R. Yu, and C. F. Bennett, “Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides,” Adv. Drug Deliv. Rev., vol. 87, pp. 46–51, 2015, doi: https://doi.org/10.1016/j.addr.2015.01.008.
[13] B. P. Monia, J. F. Johnston, H. Sasmor, and L. L. Cummins, “Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras,” J Biol Chem, vol. 271, no. 24, pp. 14533–14540, 1996, doi: 10.1074/jbc.271.24.14533.
[14] D. E. Ryan et al., “Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs,” Nucleic Acids Res, vol. 46, no. 2, pp. 792–803, 2018, doi: 10.1093/nar/gkx1199.
[15] M. Rahdar, M. A. McMahon, T. P. Prakash, E. E. Swayze, C. F. Bennett, and D. W. Cleveland, “Synthetic CRISPR RNA-Cas9–guided genome editing in human cells,” Proc. Natl. Acad. Sci., vol. 112, no. 51, pp. E7110–E7117, 2015, doi: 10.1073/pnas.1520883112.
[16] A. Mir et al., “Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing,” Nat. Commun., vol. 9, no. 1, p. 2641, 2018, doi: 10.1038/s41467-018-05073-z.
[17] E. K. Brinkman, T. Chen, M. Amendola, and Bas, “Easy quantitative assessment of genome editing by sequence trace decomposition,” Nucleic Acids Res., vol. 42, no. 22, pp. e168–e168, 2014, doi: 10.1093/nar/gku936.
[18] J. G. Doench et al., “Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation,” Nat. Biotechnol., vol. 32, no. 12, pp. 1262–1267, 2014, doi: 10.1038/nbt.3026.
[19] E. Kouranova et al., “CRISPRs for Optimal Targeting: Delivery of CRISPR Components as DNA, RNA, and Protein into Cultured Cells and Single-Cell Embryos,” Hum. Gene Ther., vol. 27, no. 6, pp. 464–475, Jun. 2016, doi: 10.1089/hum.2016.009.
[20] A. Seki and S. Rutz, “Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells,” J. Exp. Med., vol. 215, no. 3, pp. 985–997, 2018, doi: 10.1084/jem.20171626.

Previous article in this issue

Next article in this issue

Journal of Biological Methods, Electronic ISSN: 2326-9901 Print ISSN: TBA, Published by POL Scientific

Publisher's Core Philosophy

We are committed to support the scientific community by publishing impactful research and enhancing communication among scientists. At POL Scientific, we are continuously looking for ways to accelerate scientific progress and to strive for transparency and open communication, making knowledge freely accessible without barrier.

171 Skyview St. San Francisco, CA 94131 U.S.A.

info@polscientific.com